BIN1 modulation in vivo rescues dynamin-related myopathy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35217605.
- Also identified by DOI 10.1073/pnas.2109576119 and PMC identifier 8892365.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The mechanoenzyme dynamin 2 (DNM2) is crucial for intracellular organization and trafficking. <i>DNM2</i> is mutated in dominant centronuclear myopathy (DNM2-CNM), a muscle disease characterized by defects in organelle positioning in myofibers. It remains unclear how the in vivo functions of DNM2 are regulated in muscle. Moreover, there is no therapy for DNM2-CNM to date. Here, we overexpressed human amphiphysin 2 (BIN1), a membrane remodeling protein mutated in other CNM forms, in <i>Dnm2</i><sup>RW/+</sup> and <i>Dnm2</i><sup>RW/RW</sup> mice modeling mild and severe DNM2-CNM, through transgenesis or with adeno-associated virus (AAV). Increasing BIN1 improved muscle atrophy and main histopathological features of <i>Dnm2</i><sup>RW/+</sup> mice and rescued the perinatal lethality and survival of <i>Dnm2</i><sup>RW/RW</sup> mice. In vitro experiments showed that BIN1 binds and recruits DNM2 to membrane tubules, and that the BIN1-DNM2 complex regulates tubules fission. Overall, BIN1 is a potential therapeutic target for dominant centronuclear myopathy linked to DNM2 mutations.
Medical subject headings
- Adaptor Proteins, Signal Transducing
- Dynamin II
- Muscular Atrophy
- Muscular Diseases
- Nuclear Proteins
- Tumor Suppressor Proteins